In the industry, when the news that Kantangle will be out of China spread everywhere, on July 21, Kantler China’s official WeChat published an article on “Business in Kantler China”, and did not blame the news of “exit China”. The fact that it will withdraw from China is basically confirmed.

On the same day, in the exchange of cypress blue and Kantler-related executives, the other party did not deny that it was about to withdraw from China. The executive’s statement is consistent with the official WeChat.

He said that since the acquisition of Chinese companies, Kantler has been growing very well, far exceeding the industry average. At present, the medical reform has entered a new stage. To achieve growth, the company needs a strategic breakthrough, which may be considered by the company's decision makers. In the past, Kantangle's business in China was very practical, and the part that will be adjusted this time is also to strengthen competitiveness.

Earlier, Reuters revealed that Kantler is preparing to sell its business in China, and the transaction price is expected to be between 1.2 billion and 1.5 billion US dollars. Shanghai Pharmaceuticals, China Resources Pharmaceuticals and Sinopharm are among the many companies that want to buy Condé China, and will make a choice last Friday (July 22).

But after two days, no further news has been sent from all parties. It has not been decided on Friday whether the results have been made.

Machinery Enterprise World Ranking, Kantler Leju fifth

According to Medtech Insight's sales ranking for medical device companies in the world, in 2016, Kantler medical device business ranked 5th in the world medical device company with US$12.430 billion, ranking behind Medtronic, Johnson & Johnson, GE and Siemens. .

According to the "Fortune" World Top 500, which was just released on July 20th, Kantler ranked 35th in revenue of 121.546 billion US dollars in 2016, 15 times higher than 2016, and second only to United Health Group in health field. And CVS.

In terms of medical devices, Kantler acquired the Cordis of Johnson & Johnson in 2015 for US$1.9 billion, and entered the field of device production. Cordis is strong in the development and manufacture of interventional vascular technology, providing diagnostic and interventional products including diagnostic and interventional catheters, balloons, self-expanding stents, guidewires and vascular closures.

On April 18 this year, Kantler announced the acquisition of Medtronic's medical products business for US$6.1 billion and signed an acquisition agreement in cash.

Kantler China Medical Devices

Kantler entered China in 1993 and officially obtained a pharmaceutical distribution license in 2003. It is the first company to obtain such a license for foreign companies. Since 2005, the business has expanded to medical devices and OTC business; in 2010, it acquired Shanghai for US$470 million. Yongyu Medicine.

In 2012, Kantler China established Kantler Medical Equipment Consulting (Shanghai) Co., Ltd. The company's products cover a wide range of products, mainly focusing on medical equipment consumables, such as non-woven surgical gowns, isolation suits, syringes, surgical cotton fabrics, etc.

It can be said that since 2007, Kantler China has accelerated its business expansion in China. It has been in the form of mergers and acquisitions or self-employed companies in Hubei, Chongqing, Chengdu, Wuxi, Ningbo, Shenzhen, Dalian, Guangzhou, Tianjin, Wenzhou. Guizhou and others are finishing the distribution.

At least until September 2016, according to Saibailan equipment, Kantler China is still ambitious in its medical device business, and its turnover is estimated to be several billion yuan. In the field of medical device distribution in China, it should It has entered the top four; it also relies on the parent company's foundation in the US market and global distribution capabilities, and is willing to help Chinese medical device manufacturers go abroad and enter the European and American markets.

Why withdraw from China

A person who had worked in the management of Kantler revealed to Cypress that during 2014 and 2015, Kantler China was still full of ambitions and had to do a "big cause", but after 2016, it felt calm. a lot of.

He analyzed that it may be that Kantler's grasp of the policy is not very good. He believes that China's medical policy will develop according to the US model, but in fact China's policy has its own unique side, and policy changes may have made Kantler Unexpected.

Kantler's previous acquisitions in China were mostly pharmaceutical wholesale companies. The dependence on hospitals was very high. After the two-vote system was launched in 2016, there was no hope of wholesale alone, and it was difficult to have a future. Therefore, it is considered to divest the Chinese business.

For the pharmaceutical retail business acquired in previous years, he said that Kantler's business has been transformed after the acquisition, which has affected the profit margin of the retail business, and the profit margin is not as large as the outside world thinks.

With the withdrawal of Kantangle from China, its business rumors will most likely be obtained by one of Shanghai Pharmaceuticals, Sinopharm or China Resources Medicine, and the medical device business will naturally be transferred.

Cosmetic Ingredients

Cosmetics are chemical mixtures made of natural, synthetic or extracted substances with different functions as raw materials and processed through production procedures such as heating, stirring and emulsification. AMULYN mainly provides cosmetic ingredients extracted from pure natural plants, which mainly play the roles of whitening, anti-aging, moisturizing, anti-oxidation, anti-inflammatory and acne-removing, and hair care. Recommended products include astaxanthin powder, bakuchiol, hydrolyzed keratin powder, Aloe Vera Extract, etc.

Astaxanthin Powder,Bakuchiol,Hydrolyzed keratin Powder,Salicin,Aloe Vera Powder

Xi'an Gawen Biotechnology Co., Ltd , https://www.amulyn-bio.com